- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03615833
Pilot Study of Vitamin D Screening Use in Peripheral Arterial Disease Patient Over Maximum Distance Walking (First-BLINDOS)
Evaluation of a Strategy for Systematic Screening for Vitamin D Deficiency and Treatment in Case of Deficiency, on the Improvement of the Maximum Walking Distance in Patients With Stage 2 Lower Limb Arterial Disease.
The prevalence of peripheral arterial disease (PAD) is greater than 15%. PAD is associated with an increased risk of cardiovascular death, coronary heart disease and stroke, with a mortality rate of 5% per year.
Most clinical evidence supports the idea that having normal vitamin D reduces cardiovascular risk. The data suggests that normalizing vitamin D levels would have a significant impact on public health, reduce costs and help control the incidence and prevalence of cardiovascular disease.
There is also a plausible physiological theory, supported by numerous observational studies, that vitamin D supplementation should be effective in improving cardiovascular outcomes, such as blood pressure, arterial stiffness, atherosclerosis, endothelial function, and clinical events.
The investigators hypothesize that routine screening for vitamin D deficiency and supplementation in case of hypovitaminosis D is effective for improving the maximum walking distance after 12 weeks of treatment in stage 2 PAD patients .
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
At admission eligible patients are proposed to participate. Written consent is signed after complete oral and written explanation of the protocol is signed. Vitamin D level will be assessed : Patients without vitamin D deficiency will be excluded.
The influence of vitamin D supplementation on the evolution of walking distance in 12 weeks will be studied by comparing the spontaneous evolution of this walking distance, in not supplemented patients (period 1 ), and the evolution under treatment with vitamin D (period 2, afer 3 months ).
The spontaneous evolution of the walking distance will be evaluated by the difference in walking distance observed between the beginning and the end of the first Period (3 months) . The evolution of walking distance under vitamin D treatment will be evaluated by the difference in walking distance between between the beginning and the end of the second Period (3 months).
The duration of participation for a subject is equal to 6 months (2 periods of 3 months )
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 4
Kontakter og lokationer
Studiesteder
-
-
-
Angers, Frankrig, 49933
- CHU Angers
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Patients presenting a Peripheral Arterial Disease (Stage 2)
- Affiliation to the French National healthcare system
- French speaking patients
Exclusion Criteria:
- Pregnancy
- Inability to understand the study goal
- Patients protected by decision of law
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Patients with Vitamin D deficiency
Patients with Vitamin D deficiency, Administration of Cholecalciferol 2.5 mg (100 000 UI), once a month for 3 months
|
Cholecalciferol 2.5mg (100 000 UI) , once a month for 3 months
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Change of the maximum walking distance on treadmill
Tidsramme: baseline, 12 weeks and 24 weeks
|
the Walking distance will be assessed during a test on a treadmill according to a standardized procedure
|
baseline, 12 weeks and 24 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Tolerance of vitamin D supplementation during 12 weeks of treatment (period 2)
Tidsramme: 24 weeks
|
Prevalence and description of adverse events reported by the patient in a patient book and data collected at the end of treatment
|
24 weeks
|
Compliance with Vitamin D supplementation
Tidsramme: 24 weeks
|
Recording of vitamin D intake by the patient in a patient booklet and counting of the number of vitamin D boxes in the V2 visit
|
24 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Samir HENNI, MD, PhD, University Hospital, Angers
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Hjerte-kar-sygdomme
- Karsygdomme
- Åreforkalkning
- Arterielle okklusive sygdomme
- Åreforkalkning
- Perifer arteriel sygdom
- Perifere vaskulære sygdomme
- Lægemidlers fysiologiske virkninger
- Mikronæringsstoffer
- Vitaminer
- Knogletæthedsbevarende midler
- Calciumregulerende hormoner og midler
- D-vitamin
- Cholecalciferol
Andre undersøgelses-id-numre
- 2018-004146-41
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Perifer arteriel sygdom
-
Mayo ClinicTilmelding efter invitationAnatomi af GSV for Rescue Peripheral IV AccessForenede Stater
-
Universitaire Ziekenhuizen KU LeuvenUniversity of Pittsburgh; Sheba Medical Center; Mount Sinai Hospital, Canada og andre samarbejdspartnereUkendtTwin Reversal Arterial Perfusion SyndromeSpanien, Tyskland, Israel, Belgien, Holland, Canada, Forenede Stater, Østrig, Frankrig, Italien, Det Forenede Kongerige
-
University of MiamiRekrutteringTvilling til tvilling transfusionssyndrom | Tvilling; Komplicerer graviditet | Twin Reversal Arterial Perfusion Syndrome | Monokorionisk diamniotisk placenta | Monokorial monoamniotisk placentaForenede Stater
-
Boston Children's HospitalIkke rekrutterer endnuGraviditetsrelateret | Moderlige; Procedure | Fostertilstande | Twin Monochorionic Monoamniotic Placenta | Tvilling til tvilling transfusionssyndrom | Twin Reversal Arterial Perfusion Syndrome | Vasa Previa | In utero-procedure, der påvirker foster eller nyfødte | Chorion; Abnorm | ChorioangiomForenede Stater
Kliniske forsøg med Cholecalciferol
-
Medical University of South CarolinaAfsluttetD-vitamin mangel | Ernæringsmæssig mangelForenede Stater
-
Centre of Postgraduate Medical EducationUkendtSpædbørn, for tidligt fødte, SygdommePolen
-
University of PittsburghNational Heart, Lung, and Blood Institute (NHLBI)AfsluttetCystisk fibrose | Allergisk bronkopulmonal aspergilloseForenede Stater
-
Johns Hopkins UniversityNational Institute on Aging (NIA)AfsluttetD-vitamin mangel | FalderForenede Stater
-
Rashid Centre for Diabetes and ResearchAfsluttetFedme | Type 2 diabetes mellitus | Hypovitaminose DForenede Arabiske Emirater
-
University Hospital, AngersMylan LaboratoriesAfsluttet
-
Assistance Publique - Hôpitaux de ParisLaboratoire CrinexAfsluttetNyretransplantationskandidat for højre nyreFrankrig
-
University Hospitals Cleveland Medical CenterUniversity of Colorado, DenverAfsluttetBetændelseForenede Stater
-
Medical University of South CarolinaEunice Kennedy Shriver National Institute of Child Health and Human Development... og andre samarbejdspartnereAfsluttet